Company news
Eupraxia Pharmaceuticals, Inc. news in 2021
Eupraxia Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR
December 2, 2021
Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results
November 10, 2021
Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding
November 4, 2021
Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR
September 16, 2021
Eupraxia Pharmaceuticals Inc. Commences Patient Screening For Its Phase 2 Trial For Osteoarthritis Drug Candidate EP-104IAR
September 14, 2021
Eupraxia Pharmaceuticals Inc. Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 13, 2021
Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of EP-104IAR in Osteoarthritis of the Knee
July 19, 2021
Eupraxia Pharmaceuticals Inc. Announces $10 Million Convertible Debt Agreement with Silicon Valley Bank and Conversion of $6.0 Million pre-IPO Debt
June 21, 2021
Eupraxia Pharmaceuticals Inc. Announces Presentation at the Raymond James Human Health Innovations Conference
June 16, 2021
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO
May 3, 2021
Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthritis (OA) Product Candidate
April 14, 2021
Eupraxia Pharmaceuticals Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
April 13, 2021
Eupraxia Virtually Opens The Market
March 19, 2021
Eupraxia Pharmaceuticals Inc. Completes Initial Public Offering
March 9, 2021